Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Nxera Pharma Co., Ltd.. A complete text table follows the diagram.
Revenue rose 18.7%, but R&D reached JPY7.5 billion and operating loss remained JPY2.8 billion as Nxera advanced a 30-plus-program GPCR pipeline.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Cost of sales | 1 | 3.5B | 18.8% of reported total |
| Research and development | 1 | 7.5B | 40.4% of reported total |
| Selling, general and administrative | 1 | 7.6B | 40.9% of reported total |
| Operating costs | 2 | 18.5B | Cost of sales, R&D and SG&A reported under IFRS |
| Operating loss | 2 | 2.8B | Absolute value of reported operating loss |
| Operating costs & expenses | 3 | 21.3B | Revenue plus reported operating loss |
| From | To | Value |
|---|---|---|
| Cost of sales | Operating costs | 3.5B |
| Research and development | Operating costs | 7.5B |
| Selling, general and administrative | Operating costs | 7.6B |
| Operating costs | Operating costs & expenses | 18.5B |
| Operating loss | Operating costs & expenses | 2.8B |